Encompass Health Corporation $EHC Holdings Reduced by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB cut its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 12.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 119,400 shares of the company’s stock after selling 17,000 shares during the period. Encompass Health accounts for approximately 1.7% of Rhenman & Partners Asset Management AB’s portfolio, making the stock its 22nd biggest holding. Rhenman & Partners Asset Management AB’s holdings in Encompass Health were worth $15,166,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in EHC. Tectonic Advisors LLC increased its holdings in shares of Encompass Health by 1.6% in the third quarter. Tectonic Advisors LLC now owns 5,337 shares of the company’s stock valued at $678,000 after buying an additional 82 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Encompass Health by 23.0% during the third quarter. Global Retirement Partners LLC now owns 449 shares of the company’s stock worth $57,000 after purchasing an additional 84 shares during the period. EP Wealth Advisors LLC lifted its holdings in shares of Encompass Health by 2.4% during the second quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock valued at $453,000 after purchasing an additional 88 shares during the last quarter. Natural Investments LLC increased its stake in Encompass Health by 1.2% in the 3rd quarter. Natural Investments LLC now owns 7,808 shares of the company’s stock worth $991,000 after purchasing an additional 89 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its holdings in Encompass Health by 1.1% during the 3rd quarter. TD Private Client Wealth LLC now owns 8,216 shares of the company’s stock worth $1,044,000 after buying an additional 91 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Barclays upped their price objective on shares of Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Sunday, January 18th. Finally, Zacks Research lowered shares of Encompass Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Encompass Health presently has an average rating of “Buy” and a consensus target price of $143.29.

Encompass Health Price Performance

NYSE EHC opened at $106.89 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.08 and a quick ratio of 1.08. The firm has a market capitalization of $10.63 billion, a price-to-earnings ratio of 19.29, a price-to-earnings-growth ratio of 2.05 and a beta of 0.71. The company has a 50 day simple moving average of $103.93 and a 200-day simple moving average of $113.65. Encompass Health Corporation has a 52-week low of $92.53 and a 52-week high of $127.99.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Thursday, February 5th. The company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.17. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. The firm had revenue of $3.09 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the previous year, the firm posted $1.17 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. Equities research analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Wednesday, April 1st will be paid a $0.19 dividend. The ex-dividend date of this dividend is Wednesday, April 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio is 13.72%.

Insider Activity

In related news, CEO Mark J. Tarr sold 150,000 shares of Encompass Health stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $111.64, for a total transaction of $16,746,000.00. Following the completion of the sale, the chief executive officer owned 377,070 shares of the company’s stock, valued at approximately $42,096,094.80. This trade represents a 28.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.00% of the company’s stock.

About Encompass Health

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.